Kalidex Pharmaceuticals Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Kalidex Pharmaceuticals Inc.
Antibiotic Market Snapshot: In Exchange For Higher Prices, More Value
Drug developers face enormous regulatory and commercial hurdles in the antibiotics market, but industry is looking to challenge the current business model with new premium-priced drugs that deliver compelling pharmaco-economic benefits over generics.
Anti-Infective Start-Ups See Opportunity In An Epidemiological Nightmare
Infectious disease researchers have been warning for decades of the growing numbers of drug-resistant bacteria, and a certain subset of investors and companies sees this epidemiological nightmare as an alluring business opportunity. We profile three emerging anti-infective drug developers in this issue: Arsanis Biosciences, ContraFect, and Fedora Pharmaceuticals.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.